Related Experiment Video
Updated: Oct 17, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Intravenous thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis
Lele Huang1, Yujie Wang2, Ruijun Zhang3
1Department of Ophthalmology, The First Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang, 110001, People's Republic of China.
Insights
Intravenous thrombolysis (IVT) with alteplase shows potential for improving vision in central retinal artery occlusion (CRAO) patients. While IVT may enhance best-corrected visual acuity, final outcomes can be influenced by ocular complications unrelated to the treatment.
Area of Science:
- Ophthalmology
- Neurology
- Vascular Medicine
Background:
- Central retinal artery occlusion (CRAO) is a critical condition leading to vision loss.
- Investigating effective treatments for CRAO is essential for preserving sight.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous thrombolysis (IVT) using alteplase in patients diagnosed with CRAO.
- To determine the impact of IVT on visual acuity outcomes in CRAO patients.
Main Methods:
- A systematic literature search was conducted on PubMed and EMBASE for studies on IVT in CRAO patients up to May 19, 2021.
- Pooled analysis of best-corrected visual acuity (BCVA) improvement rates and mean differences (MD) using random effects models.
- Included 8 studies with 316 CRAO patients (157 treated with IVT, 159 controls).
Main Results:
- The rate of best BCVA improvement was significantly higher in the IVT group (47%) compared to the control group (12%) (OR 5.97).
- Patients receiving IVT showed better best BCVA (MD [logMAR] -0.23) compared to controls, despite similar baseline BCVA.
- No significant difference in final BCVA was observed between groups (MD [logMAR] -0.10).
- Two patients experienced symptomatic intracranial hemorrhage post-IVT.
Conclusions:
- Intravenous thrombolysis with alteplase may be an effective and safe treatment option for CRAO.
- Ocular-specific complications, independent of thrombolysis, can negatively impact final visual acuity in CRAO patients.
- Further research may be needed to optimize IVT protocols and manage potential complications.
Background And Purpose:
To investigate the efficacy and safety of intravenous thrombolysis (IVT) with alteplase in patients with central retinal artery occlusion (CRAO).
Methods:
We searched the database of PubMed and EMBASE for potentially eligible studies that reported IVT in CRAO patients from their dates of inception to May 19, 2021. The rate and odds ratios (OR) of best-corrected visual acuity (BCVA) improvement, mean difference (MD) of BCVA with 95% confidence interval (CI) were pooled with random effects model.
Results:
We included 8 studies enrolling 316 CRAO patients, among them, 157 patients received IVT with alteplase while 159 patients did not. The rate of best BCVA improvement was 47% (95% CI 33-62%) in the CRAO patients treated with IVT, which was higher than that of 12% (95% CI 1-23%) in those without IVT (OR 5.97, 95% CI [2.77-12.86]). In the setting of similar baseline BCVA (MD [logMAR] 0.16, 95% CI [- 0.15 to 0.46]), compared with those who did not receive IVT, the CRAO patients who received IVT had better best BCVA (MD [logMAR] - 0.23, 95% CI [- 0.44 to - 0.02]), but had no significant better final BCVA (MD [logMAR] - 0.10, 95% CI [- 0.32 to 0.12]). Two CRAO patients had complicated symptomatic intracranial hemorrhage after IVT.
Conclusions:
IVT treatment might be effective and safe for CRAO patients, but ocular-specific complications which were not associated with thrombolysis could affect final visual acuity.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction

